These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28072706)

  • 21. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
    Middleton G; Silcocks P; Cox T; Valle J; Wadsley J; Propper D; Coxon F; Ross P; Madhusudan S; Roques T; Cunningham D; Falk S; Wadd N; Harrison M; Corrie P; Iveson T; Robinson A; McAdam K; Eatock M; Evans J; Archer C; Hickish T; Garcia-Alonso A; Nicolson M; Steward W; Anthoney A; Greenhalf W; Shaw V; Costello E; Naisbitt D; Rawcliffe C; Nanson G; Neoptolemos J
    Lancet Oncol; 2014 Jul; 15(8):829-40. PubMed ID: 24954781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
    Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
    Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
    Haas M; Waldschmidt DT; Stahl M; Reinacher-Schick A; Freiberg-Richter J; Fischer von Weikersthal L; Kaiser F; Kanzler S; Frickhofen N; Seufferlein T; Dechow T; Mahlberg R; Malfertheiner P; Illerhaus G; Kubicka S; Abdul-Ahad A; Snijder R; Kruger S; Westphalen CB; Held S; von Bergwelt-Baildon M; Boeck S; Heinemann V
    Eur J Cancer; 2021 Mar; 146():95-106. PubMed ID: 33588150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
    Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
    Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
    Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
    J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
    J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
    Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
    Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
    Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
    Stemmler HJ; diGioia D; Freier W; Tessen HW; Gitsch G; Jonat W; Brugger W; Kettner E; Abenhardt W; Tesch H; Hurtz HJ; Rösel S; Brudler O; Heinemann V
    Br J Cancer; 2011 Mar; 104(7):1071-8. PubMed ID: 21407218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Dikiltas M; Unek IT; Colak D; Elkiran ET; Helvaci K; Geredeli C; Dane F; Balakan O; Kaplan MA; Durnali AG; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Kucukoner M; Ozkan M; Uncu D; Benekli M; Isikdogan A
    Neoplasma; 2012; 59(3):297-301. PubMed ID: 22329849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
    Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
    N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
    Courtin A; Richards FM; Bapiro TE; Bramhall JL; Neesse A; Cook N; Krippendorff BF; Tuveson DA; Jodrell DI
    PLoS One; 2013; 8(6):e67330. PubMed ID: 23840665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
    Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM
    Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
    Orlandi A; Calegari MA; Martini M; Cocomazzi A; Bagalà C; Indellicati G; Zurlo V; Basso M; Cassano A; Larocca LM; Barone C
    Clin Transl Oncol; 2016 Oct; 18(10):988-95. PubMed ID: 26742940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
    Hubner RA; Worsnop F; Cunningham D; Chau I
    Pancreas; 2013 Apr; 42(3):511-5. PubMed ID: 23462324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
    Stathopoulos GP; Syrigos K; Polyzos A; Fountzilas G; Rigatos SK; Ziras N; Potamiannou A; Tsiakopoulos I; Androulakis N; Aravantinos G; Athanasiadis A; Papakotoulas P; Georgoulias V
    Ann Oncol; 2004 Feb; 15(2):224-9. PubMed ID: 14760113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
    Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
    Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.